Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

NCT02194179 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: NVP XR 400 mg (KCR 25%)
DRUG: NVP XR 400 mg (KCR 20%)
DRUG: NVP XR 300 mg (KCR 25%)
DRUG: NVP XR 300 mg (KCR 20%)
OTHER: high-fat breakfast
DRUG: NVP IR 200 mg (Viramune®)

Sponsor

Boehringer Ingelheim